Literature DB >> 17994376

Clinically significant differences in the visual analog pain scale in acute vasoocclusive sickle cell crisis.

Bernard L Lopez1, Pamela Flenders, Linda Davis-Moon, Theodore Corbin, Samir K Ballas.   

Abstract

This study sought to determine the minimum clinically significant change in the visual analog scale (VAS) during the Emergency Department (ED) treatment of adult vasoocclusive sickle cell crisis (VOC). Sickle cell anemia patients presenting to the ED with their typical VOC pain had a 100 mm VAS administered prior to each of up to three standard analgesic injections administered as part of a treatment protocol. At each assessment, subjects were asked to describe their pain as "much better," a "little better," "the same," "a little worse," or "much worse." The change in the VAS (DeltaVAS) between assessments was measured. The main outcome of the measurement was change in the VAS associated with a description of a change in pain of "a little less" or "a little more." Seventy four subjects presented with initially high pain scores [VAS = 79.47 mm, 95% confidence interval (CI) = 75.99 to 82.95 mm]. In the "little better/little worse" combined group, the DeltaVAS was 13.5 mm (95% CI = 11.25 cm to 15.74 cm). A change in the 100 mm VAS of 13.5 mm is the minimum clinically significant change during ED treatment of VOC. A DeltaVAS <13.5 mm may not be clinically important. This finding may assist the clinician in the assessment of pain improvement for adult sickle cell patients with VOC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17994376     DOI: 10.1080/03630260701587810

Source DB:  PubMed          Journal:  Hemoglobin        ISSN: 0363-0269            Impact factor:   0.849


  8 in total

1.  Opioid patient controlled analgesia use during the initial experience with the IMPROVE PCA trial: a phase III analgesic trial for hospitalized sickle cell patients with painful episodes.

Authors:  Carlton D Dampier; Wally R Smith; Hae-Young Kim; Carrie Greene Wager; Margaret C Bell; Caterina P Minniti; Jeffrey Keefer; Lewis Hsu; Lakshmanan Krishnamurti; A Kyle Mack; Donna McClish; Sonja M McKinlay; Scott T Miller; Ifeyinwa Osunkwo; Phillip Seaman; Marilyn J Telen; Debra L Weiner
Journal:  Am J Hematol       Date:  2011-09-22       Impact factor: 10.047

2.  Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use.

Authors:  Marilyn J Telen; Ted Wun; Timothy L McCavit; Laura M De Castro; Lakshmanan Krishnamurti; Sophie Lanzkron; Lewis L Hsu; Wally R Smith; Seungshin Rhee; John L Magnani; Helen Thackray
Journal:  Blood       Date:  2015-03-02       Impact factor: 22.113

3.  The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients.

Authors:  Wally R Smith; Samir K Ballas; William F McCarthy; Robert L Bauserman; Paul S Swerdlow; Martin H Steinberg; Myron A Waclawiw
Journal:  Pain Med       Date:  2011-04-11       Impact factor: 3.750

Review 4.  What is the future of patient-reported outcomes in sickle-cell disease?

Authors:  Sharon A Singh; Nitya Bakshi; Prashant Mahajan; Claudia R Morris
Journal:  Expert Rev Hematol       Date:  2020-10-15       Impact factor: 2.929

5.  IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studies.

Authors:  Carlton D Dampier; Wally R Smith; Carrie G Wager; Hae-Young Kim; Margaret C Bell; Scott T Miller; Debra L Weiner; Caterina P Minniti; Lakshmanan Krishnamurti; Kenneth I Ataga; James R Eckman; Lewis L Hsu; Donna McClish; Sonja M McKinlay; Robert Molokie; Ifeyinwa Osunkwo; Kim Smith-Whitley; Marilyn J Telen
Journal:  Clin Trials       Date:  2013-04       Impact factor: 2.486

6.  Clinically meaningful measurement of pain in children with sickle cell disease.

Authors:  Matthew P Myrvik; Amanda M Brandow; Amy L Drendel; Ke Yan; Raymond G Hoffmann; Julie A Panepinto
Journal:  Pediatr Blood Cancer       Date:  2013-06-17       Impact factor: 3.167

Review 7.  Pain relief that matters to patients: systematic review of empirical studies assessing the minimum clinically important difference in acute pain.

Authors:  Mette Frahm Olsen; Eik Bjerre; Maria Damkjær Hansen; Jørgen Hilden; Nino Emanuel Landler; Britta Tendal; Asbjørn Hróbjartsson
Journal:  BMC Med       Date:  2017-02-20       Impact factor: 8.775

8.  Guidelines on neonatal screening and painful vaso-occlusive crisis in sickle cell disease: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular: Project guidelines: Associação Médica Brasileira - 2016.

Authors:  Josefina Aparecida Pellegrini Braga; Mônica Pinheiro de Almeida Veríssimo; Sara Teresinha Olalla Saad; Rodolfo Delfini Cançado; Sandra Regina Loggetto
Journal:  Rev Bras Hematol Hemoter       Date:  2016-04-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.